INOVAIT reveals Canada’s strategic advantages in image-guided therapy and artificial intelligence in latest report

Oct 16, 2024

TORONTO, October 16, 2024 | INOVAIT, the pan-Canadian innovation network supporting advancements and commercialization in image-guided therapy (IGT) and artificial intelligence (AI), is excited to share their latest report titled, ‘Unlocking Medtech’s Potential: Canada’s Strategic Advantages in Image-Guided Therapy & AI’. Through synthesized insights from interviews with founders and executives from 30 IGT companies in the INOVAIT Network, this new report uncovers the untapped potential of the image-guided therapy sector in Canada.

Image-guided therapy encompasses groundbreaking technologies that integrate medical imaging techniques to enhance the full spectrum of patient care from diagnostic interventions to treatment planning and execution, and post-treatment evaluation. This innovative healthcare route, championed by Sunnybrook Research Institute, is gaining traction in healthcare due to its significant improvements in patient outcomes, provider experience, and cost-effectiveness.

Key Findings: The Benefits of Building an IGT Company in Canada

The report highlights several strategic benefits identified by industry leaders for founding and operating their companies in Canada, including:

  • Research Excellence: A strong academic and research foundation fostering innovation in IGT.
  • Deep Talent Pool: Access to a skilled workforce in medicine, engineering, and technology, including world-leading specialists in AI.
  • Global Access: Opportunities for international collaboration and a geography and policy landscape enabling preferred market expansion.
  • Non-dilutive Capital: Availability of funding sources including those from government that do not require relinquishing equity.
  • Capital Efficiency: An environment conducive to developing cost-effective businesses and technologies.
  • Supportive Community: A collaborative network that promotes resource-sharing and knowledge exchange.

Overall, this report emphasizes that Canada possesses unique advantages to fortify a global stronghold in IGT innovation.

As the global medtech landscape continues to evolve, this report serves as a landmark resource for stakeholders seeking to understand the unique benefits of Canada’s IGT sector. By capturing the authentic voices of Canadian industry leaders, INOVAIT showcases not only the potential of Canadian companies but also the collaborative spirit driving advancements and commercialization in healthcare technology.

You can review the full report here: www.inovait.ca/reports

Share this on social media

Learn more about the network

Seeing beneath the surface: How MIMOSA is transforming wound care

Seeing beneath the surface: How MIMOSA is transforming wound care

Dr. Karen Cross, a plastic and reconstructive surgeon and CEO of MIMOSA Diagnostics, saw countless patients with diabetes and chronic wounds in her clinic. People with diabetes have an increased risk of developing pressure wounds due to complications like poor circulation and nerve damage. Many of her patients came into her clinic too late to prevent complications and ultimately had lower extremity amputations to prevent fatal infections.

INOVAIT publishes framework for responsibly unlocking Canadian health data for innovation and better patient care

INOVAIT publishes framework for responsibly unlocking Canadian health data for innovation and better patient care

Industry members in the INOVAIT Network are developing AI technologies that are revolutionizing the diagnosis and treatment of disease and improving patient outcomes while building the Canadian healthcare economy. The health data these companies need to create their technologies most often reside with Canadian healthcare institutions that are reluctant to share data with commercial partners due to caution stemming from a lack of clarity in privacy legislation and historical practices focused primarily on minimizing privacy and security risks.